Stephen Basham

Stephen Basham is the Vice President of Quantitative Biology at Eikon Therapeutics. Prior to this role, Stephen held positions at Nurix Therapeutics, Novartis Institutes for BioMedical Research, Chiron Corporation, Exelixis, and Genentech. With a Ph.D. in Cell and Developmental Biology from the University of California, Davis, Stephen has extensive experience in managing teams, leading drug discovery projects, and developing cell-based assays for various therapeutic areas including oncology, immunoncology, and inflammation. Stephen has been instrumental in progressing small molecule programs to clinical development and is highly skilled in assay technologies and profiling compounds.